×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARQT – arcutis biotherapeutics, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARQT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
11:12 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors [Yahoo! Finance]
11/20
11:12 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average [Yahoo! Finance]
11/19
10:51 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average [Yahoo! Finance]
Medium
Report
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average [Yahoo! Finance]
11/19
08:20 am
arqt
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors [Yahoo! Finance]
Medium
Report
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors [Yahoo! Finance]
11/13
08:00 am
arqt
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
Low
Report
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
11/7
08:36 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
11/7
02:31 am
arqt
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... [Yahoo! Finance]
Medium
Report
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... [Yahoo! Finance]
11/7
02:26 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
7.7%
arcutis biotherapeutics, inc. - common stock
8/14/2024
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
-11.3%
arcutis biotherapeutics, inc. - common stock
5/14/2024
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
13.7%
arcutis biotherapeutics, inc. - common stock
2/27/2024
05:50 am
arqt
arcutis biotherapeutics, inc. - common stock
MISS
Report
7.7%
arcutis biotherapeutics, inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
07:53 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Nov 18 Filed by: Matsuda Masaru
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Nov 18 Filed by: Matsuda Masaru
11/19
04:25 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Matsuda Masaru
Low
Report
Form 144 Arcutis Biotherapeutics, Filed by: Matsuda Masaru
11/18
07:05 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Nov 14 Filed by: Burnett Patrick
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Nov 14 Filed by: Burnett Patrick
11/15
04:32 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick
Low
Report
Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick
11/14
07:51 pm
arqt
Form SC 13G/A Arcutis Biotherapeutics, Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SC 13G/A Arcutis Biotherapeutics, Filed by: Point72 Asset Management, L.P.
11/14
05:00 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick
Medium
Report
Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick
11/13
06:45 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Nov 11 Filed by: Curran Terrie
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Nov 11 Filed by: Curran Terrie
11/13
04:31 pm
arqt
Form SC 13G/A Arcutis Biotherapeutics, Filed by: Rubric Capital Management LP
Medium
Report
Form SC 13G/A Arcutis Biotherapeutics, Filed by: Rubric Capital Management LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Form 10-K Arcutis Biotherapeutics, For: Dec 31
33.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
TOP News Decliners
3/16
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis
-16.2%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: